<?xml version='1.0' encoding='utf-8'?>
<document id="17489643"><sentence text="Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential." /><sentence text="Overactive bladder (OAB) is highly prevalent in the older population and decreases quality of life" /><sentence text=" Current therapy consists primarily of anticholinergic drugs" /><sentence text=" Because older individuals typically take multiple medications, clinicians must pay special attention to potential drug-drug interactions that may cause adverse events or alter drug efficacy" /><sentence text=" The most clinically important drug-drug interactions occur during cytochrome P450 (CYP450) isoenzyme metabolism, resulting in altered metabolism of one or more of the coadministered agents" /><sentence text=" Of the drugs indicated for OAB, tolterodine, darifenacin, solifenacin, and oxybutynin are extensively metabolized by CYP450, but trospium is not"><entity charOffset="28-31" id="DDI-PubMed.17489643.s6.e0" text="OAB" /><entity charOffset="33-44" id="DDI-PubMed.17489643.s6.e1" text="tolterodine" /><entity charOffset="46-57" id="DDI-PubMed.17489643.s6.e2" text="darifenacin" /><entity charOffset="59-70" id="DDI-PubMed.17489643.s6.e3" text="solifenacin" /><entity charOffset="76-86" id="DDI-PubMed.17489643.s6.e4" text="oxybutynin" /><entity charOffset="130-138" id="DDI-PubMed.17489643.s6.e5" text="trospium" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e0" e2="DDI-PubMed.17489643.s6.e0" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e0" e2="DDI-PubMed.17489643.s6.e1" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e0" e2="DDI-PubMed.17489643.s6.e2" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e0" e2="DDI-PubMed.17489643.s6.e3" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e0" e2="DDI-PubMed.17489643.s6.e4" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e0" e2="DDI-PubMed.17489643.s6.e5" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e1" e2="DDI-PubMed.17489643.s6.e1" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e1" e2="DDI-PubMed.17489643.s6.e2" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e1" e2="DDI-PubMed.17489643.s6.e3" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e1" e2="DDI-PubMed.17489643.s6.e4" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e1" e2="DDI-PubMed.17489643.s6.e5" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e2" e2="DDI-PubMed.17489643.s6.e2" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e2" e2="DDI-PubMed.17489643.s6.e3" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e2" e2="DDI-PubMed.17489643.s6.e4" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e2" e2="DDI-PubMed.17489643.s6.e5" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e3" e2="DDI-PubMed.17489643.s6.e3" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e3" e2="DDI-PubMed.17489643.s6.e4" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e3" e2="DDI-PubMed.17489643.s6.e5" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e4" e2="DDI-PubMed.17489643.s6.e4" /><pair ddi="false" e1="DDI-PubMed.17489643.s6.e4" e2="DDI-PubMed.17489643.s6.e5" /></sentence><sentence text=" Trospium is eliminated as unchanged drug, suggesting that it has lower potential for drug-drug interactions and may, therefore, represent a safer treatment option for OAB, particularly in the context of polypharmacy, a significant concern in older adults"><entity charOffset="168-175" id="DDI-PubMed.17489643.s7.e0" text="OAB" /></sentence><sentence text="" /></document>